The Exchange has sought clarification from Supriya Lifescience Limited for the quarter ended 30-Jun-2025 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Segment details not submitted The response of the Company is awaited.
SUPRIYA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
NSE has asked Supriya Lifescience to explain why segment-wise details were not submitted along with its financial results for the quarter ended 30 June 2025, under Regulation 33 of SEBI's Listing Obligations and Disclosure Requirements. The query is purely procedural and relates to incomplete disclosure in the results filing. No financial figures or specific reasons have been mentioned in the announcement. The company has not yet submitted its response to the exchange. This appears to be a routine compliance reminder rather than a punitive action.
This is a minor compliance lapse and is unlikely to materially affect the stock or shareholders. Investors should wait for the company's response to confirm the issue has been addressed.